Bleeding Disorders

Bleeding Disorders

A collection of features and news articles published in ASH Clinical News related to bleeding disorders.

Bluebird Bio Wins European Approval for First Beta Thalassemia Gene Therapy

Bluebird Bio’s one-time gene therapy, Zynteglo, has been cleared by EU regulators for the treatment of beta thalassemia in patients aged 12 and older....

India Sees Decline in Cases of Severe Anemia

India is home to one-quarter of patients with severe anemia, but a new report from the country’s Health Management Information System found that incidence...

Early Phase Trial Shows PB2452 Immediately Reverses Ticagrelor’s Antiplatelet Activity

The monoclonal antibody fragment PB2452 effectively and immediately reversed the antiplatelet effects of ticagrelor in healthy volunteers, according to results from a phase I...
Alexis Thompson, MD, MPH and Thomas Coates, MD

Are New Treatment Options for Beta Thalassemia Ready for Widespread Use?

Patients with transfusion-dependent beta thalassemia, the most severe form of the disease, require lifelong management with red blood cell (RBC) transfusions, presenting a substantial...
WIB_icon

Higher Dose, Longer Duration of Eltrombopag Improves Likelihood of Response in Refractory Severe Aplastic...

The thrombopoietin receptor agonist eltrombopag was approved by the U.S. Food and Drug Administration for the treatment of adults with refractory severe aplastic anemia...

FDA Approves First Anticoagulant for Pediatric Patients

The U.S. Food and Drug Administration (FDA) approved dalteparin sodium, administered as a subcutaneous injection, to reduce the recurrence of symptomatic venous thromboembolism (VTE)...

Demystifying Genetic Testing for Bleeding Disorders

When hemophilia and von Willebrand disease (vWD) were first recognized, doctors didn’t diagnose a patient until he (or, much more infrequently, she) experienced a...
On location

Beta-Thalassemia Gene Therapy Continues to Show Efficacy in Longer-Term Follow-up

Updated results from the phase I/II HGB-204 and HGB-207 trials indicated that several patients with severe, transfusion-dependent beta-thalassemia have remained transfusion-free up to four...

Xarelto Manufacturers Settle Lawsuits Over Bleeding Risks

Johnson & Johnson and Bayer, the manufacturers of rivaroxaban (sold as Xarelto), have agreed to pay $775 million to settle thousands of lawsuits over...

EU Panel Recommends Approving Gene Therapy for Thalassemia

Europe’s Committee for Medicinal Products for Human Use (CHMP) recommended approval of Bluebird Bio’s lentiglobin gene-therapy product for patients with transfusion-dependent beta-thalassemia. CHMP is...
Advertisement

Current Issue

June 2019, Volume 5, Issue 7

This issue features a debate about new treatment options for beta-thalassemia, a look at what’s driving skyrocketing drug prices in myeloma, and more.